Literature DB >> 11562079

Suppression of IL-8 gene expression by radicicol is mediated through the inhibition of ERK1/2 and p38 signaling and negative regulation of NF-kappaB and AP-1.

Y J Na1, Y J Jeon, J H Suh, J S Kang, K H Yang, H M Kim.   

Abstract

We show that radicicol, an anti-fungal agent, inhibits interleukin-8 (IL-8) production by the human monocyte line THP-1 in response to phorbol-12-myristate-13-acetate/lipopolysaccharide (PMA/LPS). IL-8 is a potent chemokine and needs for an optimal immune response--such as inflammation by activation of neutrophils. The decrease in PMA/LPS-induced IL-8 mRNA expression was demonstrated by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Since the promoter in IL-8 gene contains binding motifs for NF-KB, AP-1. and NF-IL6, which appear to be important in IL-8 induction, the effects of radicicol on the activation of these transcription factors were examined. Treatment of radicicol to THP-1 cells produced a strong inhibition of NF-KB and AP-1, while NF-IL6 was not significantly affected by radicicol. Western blot analysis showed that radicicol inhibited the phosphorylation and phosphotransferase activities of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and p38. PD98059 and SB203580, known as a specific inhibitor of MEKI and p38 kinase, respectively, inhibited IL-8 gene expression showing that both of the kinase pathways are involved in IL-8 regulation in human monocytes. Collectively, this series of experiments indicates that radicicol inhibits IL-8 gene expression by blocking ERK1/2 and p38 signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562079     DOI: 10.1016/s1567-5769(01)00113-8

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.

Authors:  Noriaki Sunaga; Hisao Imai; Kimihiro Shimizu; David S Shames; Seiichi Kakegawa; Luc Girard; Mitsuo Sato; Kyoichi Kaira; Tamotsu Ishizuka; Adi F Gazdar; John D Minna; Masatomo Mori
Journal:  Int J Cancer       Date:  2011-08-03       Impact factor: 7.396

2.  Effects of methyl gallate and gallic acid on the production of inflammatory mediators interleukin-6 and interleukin-8 by oral epithelial cells stimulated with Fusobacterium nucleatum.

Authors:  Mi-Sun Kang; Hee-Sook Jang; Jong-Suk Oh; Kyu-Ho Yang; Nam-Ki Choi; Hoi-Soon Lim; Seon-Mi Kim
Journal:  J Microbiol       Date:  2010-02-04       Impact factor: 3.422

3.  Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.

Authors:  Taly Weiss; Itamar Shalit; Hannah Blau; Sara Werber; Drora Halperin; Avital Levitov; Ina Fabian
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

4.  Wnt6 contributes tumorigenesis and development of colon cancer via its effects on cell proliferation, apoptosis, cell-cycle and migration.

Authors:  Xiao-Li Zheng; Hong-Gang Yu
Journal:  Oncol Lett       Date:  2018-05-16       Impact factor: 2.967

5.  Modeling drug mechanism of action with large scale gene-expression profiles using GPAR, an artificial intelligence platform.

Authors:  Shengqiao Gao; Lu Han; Dan Luo; Gang Liu; Zhiyong Xiao; Guangcun Shan; Yongxiang Zhang; Wenxia Zhou
Journal:  BMC Bioinformatics       Date:  2021-01-07       Impact factor: 3.169

6.  Enhanced inhibitory effect of ultra-fine granules of red ginseng on LPS-induced cytokine expression in the monocyte-derived macrophage THP-1 cells.

Authors:  Hyoung-Cheol Lee; Radhakrishnan Vinodhkumar; Jang W Yoon; Seong-Kyu Park; Chang-Won Lee; Hong-Yeoul Kim
Journal:  Int J Mol Sci       Date:  2008-08-07       Impact factor: 6.208

7.  The role of galectin-3 in the tumorigenesis and progression of pituitary tumors.

Authors:  Bo Diao; Ying Liu; Guo-Zheng Xu; Yi Zhang; Jun Xie; Jie Gong
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.